Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.

Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK.

Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29.

PMID:
31142661
2.

Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.

Singhal H, Greene ME, Zarnke AL, Laine M, Al Abosy R, Chang YF, Dembo AG, Schoenfelt K, Vadhi R, Qiu X, Rao P, Santhamma B, Nair HB, Nickisch KJ, Long HW, Becker L, Brown M, Greene GL.

Oncotarget. 2017 Sep 28;9(4):4282-4300. doi: 10.18632/oncotarget.21378. eCollection 2018 Jan 12.

3.

Effects of Combination of Estradiol with Selective Progesterone Receptor Modulators (SPRMs) on Human Breast Cancer Cells In Vitro and In Vivo.

Nair HB, Santhamma B, Krishnegowda NK, Dileep KV, Nickisch KJ.

PLoS One. 2016 Mar 24;11(3):e0151182. doi: 10.1371/journal.pone.0151182. eCollection 2016.

4.

An efficient model of human endometriosis by induced unopposed estrogenicity in baboons.

Nair HB, Baker R, Owston MA, Escalona R, Dick EJ, VandeBerg JL, Nickisch KJ.

Oncotarget. 2016 Mar 8;7(10):10857-69. doi: 10.18632/oncotarget.7516.

Supplemental Content

Loading ...
Support Center